Retatrutide Peptide Guide
Retatrutide (LY3437943) is an investigational “triple agonist” (GLP-1, GIP, and glucagon receptor activity) being studied for obesity and metabolic outcomes. This page summarizes what’s promising, what’s uncertain, and what to watch for in the data—without hype or protocol instructions.
What is Retatrutide?
Retatrutide is a lab-designed peptide being studied for obesity and metabolic disease. It is engineered to act like incretins (GLP-1 and GIP) plus glucagon signaling. That combination can shift both food intake and how the body handles fuel.
Educational information only. Not medical advice.
Benefits
- Lower hunger and fewer cravings
- Large reductions in body weight in studied populations
- Improved blood sugar markers in people with dysglycemia
Mechanism of action
Primary pathways (studied):
- Appetite regulation via brain-gut signaling
- Glucose-dependent insulin secretion and improved glycemic control
- Slower gastric emptying
- Glucagon pathway activation that may increase energy expenditure
Cell-level effects (studied):
- Increases glucose-dependent insulin release
- Shifts liver fuel handling and may increase fat oxidation signals
System-level effects (studied):
- Lower appetite and reduced calorie intake
- Meaningful body weight reduction
- Improved glucose markers in studied populations
Half-life
Half-life: Several days (long-acting), not fully established across populations.
Duration: Not fully established
Peak time: Not fully established
Storage
Storage depends on formulation (lyophilized powder vs reconstituted solution) and the manufacturer. Follow the product label when available.
- Dry / lyophilized: commonly kept cool, dry, and protected from light.
- Reconstituted: commonly refrigerated and used within the supplier’s stated window.
- Avoid: repeated heat exposure and unnecessary freeze–thaw cycles.
Reconstitution guide
For measurement math (mg, mL, and U-100 units), use:
Protocol overview
Protocol pages summarize common research-style structures and measurement concepts. They do not provide individualized instructions.
Educational information only. Not medical advice.
Research review and sources
Key research takeaways surfaced on this page
- In clinical research for obesity, retatrutide has produced large average weight loss.
- Side effects are most commonly gastrointestinal and resemble incretin-class effects.
- Long-term durability after stopping and long-term safety are not fully established.
Primary references and supporting sources
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial — Primary obesity trial that shapes the current weight-loss and GI-tolerability conversation.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial — Adds liver-fat and metabolic-outcome context in a human trial setting.
Dosage and calculator
Suggested links
For educational and research purposes only. Not medical advice. Consult a licensed healthcare professional for personal guidance.